15 results about "Bone cancer" patented technology

The present application relates to the field of polymer chemistry and biomedical technology, and particularly relates to a macrocyclic lactone polymer shown in formula (I) which is used for preventing or treating hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Barrett's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer, bladder cancer, colorectal cancer and melanoma, and has the potential to be developed into a new type of antitumor drug.

The ester derivatives of brefeldin A represented by Formula (I) in the inhibition of tumor proliferation. The compounds are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Bart's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer and colorectal cancer, and have the potential to be developed as antitumor agents.

This patent application belongs to the field of antibody technology, specifically relating to an anti-NGF monoclonal antibody and its applications. The anti-NGF monoclonal antibody of this patent application can specifically bind to TrkA and p75. The anti-NGF monoclonal antibody of this patent application can be used to treat or prevent NGF-mediated diseases, such as autoimmune arthritis, bone cancer pain, osteoarthritis, and fracture pain.

The present invention relates to a non-invasive magneto-acoustic apparatus for healthy tissue healing and cancer regression comprising at least one pulsed ultrasound unit (LIPUS), at least one permanent magnet, at least one module housing, at least one permanent magnets, at least one control system for controlling pulsed ultrasound unit to energize the unit with desired pulse duration, intensity and active / ON time. The invention is to synchronously use the low intensity pulsed ultrasound (LIPUS) and static magnetic field (SMF) to selectively activate cellular activities specific to cartilage, bone, skin leading to accelerated tissue healing, regeneration. The invention apparatus is to inhibit cancer cellular activities specific to cancers of breast, skin, bone leading to enhanced cancer regression, while leaving the healthy cells unaffected using magneto-acoustic apparatus appropriately. The apparatus exhibit no toxicity to healthy cells and can reduce overall treatment time and costs due to accelerated tissue repair and tumor regression.

The invention belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound to preparation of a medicine for treating cancer, the structural formula of the benzothiazepine compound is shown in the formula I, and the cancer is selected from at least one of liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment, the compound shown in the formula I shows clear and different activities of resisting human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventor of the invention finds that the benzothiazepine compound as shown in the formula I has excellent activity on various different types of human tumors for the first time by performing activity screening on a small molecular skeleton, and provides an optional scheme for broad-spectrum anti-cancer drugs.

The present disclosure provides compositions and methods of treating bone cancers, e.g., osteosarcoma in a patient whose age is, for example, at least 2 years old, or at least 12 years old. The method comprises promoting the opening of Cx43 hemichannel in osteocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.

The present disclosure provides compositions and methods for treating osteosarcoma, such as osteosarcoma in a patient who has previously received at least one first-tier osteosarcoma treatment but has failed treatment. The methods comprise promoting the opening of Cx43 hemichannels in bone cells by, for example, using a composition comprising an anticonnexin 43 antibody.

The application belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound in preparation of a cancer treatment drug, wherein the benzothiazepine compound has a structural formula as shown in formula I, and the cancer is at least one selected from liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment of the application, it is found that the compound shown in formula I shows clear and different activities on human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventors of the application find, for the first time, through activity screening on a small molecule skeleton, that the benzothiazepine compound shown in formula I has excellent activity on various different types of human tumors, and the benzothiazepine compound provides an optional scheme for a broad-spectrum anticancer drug.

The invention provides a PLGA (poly (lactic-co-glycolic acid)-PEG (polyethylene glycol)-phosphonate polymer, a bone targeting nanoparticle as well as a preparation method and application of the bone targeting nanoparticle. According to the preparation method of the PLGA-PEG-phosphonate polymer, no catalyst is needed to participate in the reaction, the reaction can be carried out at room temperature, and the preparation method is a green chemical reaction method and is more suitable for large-scale process production requirements; the bone targeting nanoparticle is formed by self-assembly of the PLGA-PEG-phosphonate polymer and PLGA-PEG, the nanoparticle can be specifically combined with hydroxyapatite in bone tissue to realize targeting of the bone tissue, and the nanoparticle can be used as a drug carrier to deliver drugs to the bone tissue, so that the bone targeting nanoparticle has a good application prospect. And bone tissue related diseases such as osteoporosis, bone cancer and osteoarthritis can be treated.

The present disclosure relates to the field of medicinal chemistry, and specifically to brefeldin A derivatives represent by Formula (I) and its use in the inhibition of tumor proliferation activity. The new compounds provided herein are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, lung cancer, Bart's esophageal cancer, gastric cancer, cervical cancer, pancreatic cancer, kidney cancer, endometrial cancer, nasopharyngeal cancer, bone cancer, lymphoma, brain cancer, nerve cancer, oral cancer and colorectal cancer, and have the potential to be developed as novel antitumor agents.

The composition and method for ex vivo expansion of stem cell memory T cells provided by the embodiments of the present disclosure can amplify and culture a cell population with a higher proportion of memory T stem cells, a higher combined proportion of memory T stem cells and central memory T cells, and a higher proportion of natural killer T cells compared to other processes. Additionally, the obtained cell population demonstrates excellent cytotoxic effects against bone cancer and pancreatic cancer cell lines, leading to the production of cell products with enhanced cell therapy efficacy.

The present invention belongs to the technical field of antibodies. Provided are an anti-NGF monoclonal antibody and the use thereof. The anti-NGF monoclonal antibody can specifically bind to TrkA and p75, and can be used for treating or preventing related NGF-mediated diseases, such as autoimmune arthritis, bone-cancer-related pain, osteoarthritis, and fracture-related pain.

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of SLC26A2, such as certain ovarian, endometrial, brain, bone, and lung cancers, as well as melanoma. A previously identified vanadium-containing compound, bis(maltolato)oxovanadium(IV) (BMOV), specifically provided for killing of SLC26A2 expressing cancer cells in a SLC26A2-dependent manner. The instant disclosure therefore provides for selecting and / or administering BMOV and related vanadium-containing compounds as a therapeutic agent to target a cancer cell and / or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.

GREM2 compositions and formulations thereof for treating or preventing one or more symptoms of a disease associated with loss of bone mineral density are described. Recombinant GREM2 has been demonstrated to be capable of reducing bone resorption, lowering bone transition markers, and increasing bone strength. Methods of using the GREM2 compositions and formulations are also provided. Preferably, the pharmaceutical formulation containing GREM2 is administered by a parenteral route to prevent or alleviate one or more symptoms of osteoporosis, bone mass reduction, bone fracture and / or bone cancer.